Felicia Longobardi: Since 1998, Medtronic has pioneered the ICM market, consistently innovating based on evolving customer feedback and patient needs. The LINQ family of ICMs help clinicians identify or rule out heart rhythm disorders so patients can receive the right course of treatment to manage their condition.

The Reveal LINQ ICM and LINQ II ICM are inserted just under the skin on the chest and monitor the heart continuously for up to several years. ICMs are ideal for patients with heart rhythm abnormalities that may require long-term monitoring or ongoing management.

In 2014, we initiated a miniaturization revolution that led to the introduction of the world’s smallest ICM, the Reveal LINQ ICM. From there, we advanced to the LINQ II ICM, introducing remote monitoring, BlueSync technology, and now artificial intelligence algorithms that help reduce false alerts.

Incorporating real-world ICM data and AI into our R&D and product development has propelled us toward disease management and true patient-centred care that connects patients and physicians for comprehensive insights and recommendations.

The future is exciting as we continue to transform our data into clinical decisions, offering a bright prospect for both patients and healthcare providers.

Exec Chat: Data Insights And AI Are Maximizing The Value Of Medtronic’s ICM Family

AI Performed In The Cloud Frees Up R&D

More from Cardiology

More from Device Area